The latest price target for Atea Pharmaceuticals (NASDAQ:AVIR) was reported by Morgan Stanley on August 13, 2024. The analyst firm set a price target for $6.88 expecting AVIR to rise to within 12 months (a possible 76.41% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Atea Pharmaceuticals (NASDAQ:AVIR) was provided by Morgan Stanley, and Atea Pharmaceuticals upgraded their equal-weight rating.

The last upgrade for Atea Pharmaceuticals Inc happened on August 13, 2024 when Morgan Stanley raised their price target to $6.88. Morgan Stanley previously had an underweight for Atea Pharmaceuticals Inc.

The last downgrade for Atea Pharmaceuticals Inc happened on August 10, 2023 when JP Morgan changed their price target from N/A to N/A for Atea Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atea Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atea Pharmaceuticals was filed on August 13, 2024 so you should expect the next rating to be made available sometime around August 13, 2025.

While ratings are subjective and will change, the latest Atea Pharmaceuticals (AVIR) rating was a upgraded with a price target of $2.00 to $6.88. The current price Atea Pharmaceuticals (AVIR) is trading at is $3.90, which is within the analyst’s predicted range.